Immutep Limited (YP1A) - Total Assets
Based on the latest financial reports, Immutep Limited (YP1A) holds total assets worth €147.20 Million EUR (≈ $172.09 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See how leveraged is Immutep Limited's balance sheet to measure how much of total assets are equity-financed.
Immutep Limited - Total Assets Trend (2017–2024)
This chart illustrates how Immutep Limited's total assets have evolved over time, based on quarterly financial data. Check Immutep Limited (YP1A) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Immutep Limited - Asset Composition Analysis
Current Asset Composition (June 2024)
Immutep Limited's total assets of €147.20 Million consist of 94.9% current assets and 5.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 80.3% |
| Accounts Receivable | €5.24K | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €8.13 Million | 4.0% |
| Goodwill | €109.96K | 0.1% |
Asset Composition Trend (2017–2024)
This chart illustrates how Immutep Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see YP1A market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immutep Limited's current assets represent 94.9% of total assets in 2024, an increase from 45.5% in 2017.
- Cash Position: Cash and equivalents constituted 80.3% of total assets in 2024, up from 35.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 54.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 4.0% of total assets.
Immutep Limited Competitors by Total Assets
Key competitors of Immutep Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Immutep Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.97 | 18.86 | 11.94 |
| Quick Ratio | 2.97 | 18.86 | 11.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €92.78 Million | €164.55 Million | €57.05 Million |
Immutep Limited - Advanced Valuation Insights
This section examines the relationship between Immutep Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.84 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | 36.7% |
| Total Assets | €201.58 Million |
| Market Capitalization | $53.07 Million USD |
Valuation Analysis
Below Book Valuation: The market values Immutep Limited's assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Immutep Limited's assets grew by 36.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Immutep Limited (2017–2024)
The table below shows the annual total assets of Immutep Limited from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | €201.58 Million ≈ $235.67 Million |
+36.71% |
| 2023-06-30 | €147.45 Million ≈ $172.38 Million |
-0.72% |
| 2022-06-30 | €148.52 Million ≈ $173.64 Million |
+81.06% |
| 2021-06-30 | €82.03 Million ≈ $95.90 Million |
+76.04% |
| 2020-06-30 | €46.60 Million ≈ $54.48 Million |
+14.94% |
| 2019-06-30 | €40.54 Million ≈ $47.40 Million |
-13.74% |
| 2018-06-30 | €47.00 Million ≈ $54.95 Million |
+34.42% |
| 2017-06-30 | €34.96 Million ≈ $40.88 Million |
-- |
About Immutep Limited
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more